Skip to main content
Martin Harp on Muck Rack

Martin Harp

Verified
(He/Him)
Cleveland
As seen in: Modern Retina, Ophthalmology Times, Optometry Times, WhatCulture, WhatCulture Gaming, NewsBreak, TheGamer, Ophthalmology Times Europe, CGTLive
Writer on the webs | Former Co-Host @gimmickpod | Music Snob | Movie Buff | Video Game Nerd | Wrestling Fan | Sports Enthusiast

Get in touch with Martin

Contact Martin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Martin Harp’s Biography

Read Full Bio →

My name is Martin David Harp and I am an editor/writer that loves all things spooky, creepy and weird.

Articles

THN391 enters phase 1b trial for diabetic macular edema

|
By Ian C. Han, Alex Nixon, Martin Harp Verified
| Modern Retina
Therini Bio has dosed the first patients in a phase 1b multiple ascending dose trial evaluating THN391, an investigational intravitreal anti-inflammatory monoclonal antibody, for diabetic macular edema (DME).1 The early-stage study is intended to assess the safety and preliminary biological activity of a fibrin-targeting approach in a disease currently treated primarily with anti–vascular endothelial growth factor (VEGF) agents.
Open in Who Shared Issue with article?

Retina World Congress 2026: RVO as a window into systemic vascular health

|
By Michael S. Ip, Martin Harp Verified, Katherine Talcott
| Modern Retina
Katherine Talcott, MD, a retinal surgeon at the Cole Eye Institute Institute at Cleveland Clinic, sat down with Modern Retina for the 2026 Retina World Congress (RWC), held May 14–17, at the Marriott Harbor Beach Resort in Fort Lauderdale, Florida.
Open in Who Shared Issue with article?

Geographic atrophy topography and quality of life: What the central 2.5-mm region reveals

|
By Martin Harp Verified, Sheryl Stevenson Verified, Jay Chhablani
| Modern Retina
The topographic distribution of geographic atrophy (GA) within the central 2.5-mm diameter region of the macula is more strongly associated with vision-related quality of life (VR-QoL) than foveal involvement alone, according to a new analysis published in Ophthalmology.1 The findings, drawn from the phase 3 Chroma (NCT02247479) and Spectri (NCT02247531) trials of lampalizumab, have implications for how GA extent is evaluated in both clinical trials and clinical practice.
Open in Who Shared Issue with article?
See all 418 licensed articles (1,987 Total)

Interview

See all →

What was your first job as a journalist?

I was an intern at Cleveland Scene Magazine covering music and entertainment

What's your favorite social network?

Take me back to when Myspace was king of the mountain

What's your favorite drink?

Coffee